Patent ID: 8263602

Claim:
A method for treating chronic obstructive pulmonary disease (COPD), which comprises administering an effective amount of a compound of formula (Ia) or (Ib) to a human subject in need thereof: wherein: T is absent or represents —O—, —S—, —NR 16 or —CR 16 R 17 ; --- represents optional bonds; G 1 and G 2 each independently represents —CH— or —N—; A represents bond, —C 1-6 alkyl or —CH═CH—C 1-4 alkyl; B represents bond, —O—, —S—, —SO—, —SO 2 —, —CO—, —CR 7 R 8 , —CO 2 R 14 , —CONR 14 R 15 , —N(COR 14 )(COR 15 ), —N(SO 2 R 14 )(COR 15 ), or —NR 14 R 15 ; wherein R 7 and R 3 each independently represent H, halo, C 1-6 alkyl or C 1-4 alkylaryl; wherein R 14 and R 15 each independently represent H, C 1-6 alkyl, C 1-4 alkylaryl or C 1-4 alkylheteroaryl or together with the functionality to which they are attached R 14 and R 15 form a heterocyclic or fused heterocyclic group which may contain one or more further atoms selected from C, O, N and S; D represents bond, or —C 1-6 alkyl; E represents substituted aryl or substituted or unsubstituted heteroaryl; wherein: heteroaryl is selected from mono- or bicyclic heterocyclic aromatic containing 1-3 hetero atoms selected from nitrogen, oxygen and sulphur; wherein aryl or heteroaryl is substituted by one or more substituents selected from C 1-6 alkyl, C 2-6 alkenyl, halogen, C 1-6 alkoxy, cyano, hydroxy, nitro, amino, —N(CH 3 ) 2 , —NHCOC 1-6 alkyl, —OCF 3 , —CF 3 , —COOC 1-6 alkyl, —OCHCF 2 , —SCF 3 , —CONR 5 R 6 , —SO 2 N(CH 3 ) 2 , —SO 2 CH 3 or —SCH 3 groups, or unsubstituted or substituted fused cycloalkyl or heterocyclic rings, wherein fused cycloalkyl or heterocyclic rings optionally are substituted by carbonyl groups; wherein R 5 and R 6 each independently represent H, C 1-6 alkyl or C 1-4 alkylaryl; R 18 and R 19 each independently represents halo, cyano, nitro, —OR 16 , —SR 16 , —COR 16 , —NR 17 COR 16 , —CONR 16 R 17 , optionally substituted phenoxy or —C 1-6 alkyl optionally substituted by —OR 16 ; wherein: R 16 represents H, —C 1-6 alkyl or —C 1-4 alkylaryl; wherein R 17 represents H or —C 1-6 alkyl; m and n each independently represents 0 or an integer 1, 2 or 3; or a pharmaceutically acceptable salt thereof.